{"id":"NCT04687072","sponsor":"argenx","briefTitle":"A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-16","primaryCompletion":"2023-10-09","completion":"2023-10-09","firstPosted":"2020-12-29","resultsPosted":"2024-10-31","lastUpdate":"2024-10-31"},"enrollment":207,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Thrombocytopenia"],"interventions":[{"type":"BIOLOGICAL","name":"Efgartigimod PH20 SC","otherNames":["ARGX-113 PH20 SC"]},{"type":"OTHER","name":"Placebo PH20 SC","otherNames":[]}],"arms":[{"label":"Efgartigimod PH20 SC","type":"EXPERIMENTAL"},{"label":"Placebo PH20 SC","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP.","primaryOutcome":{"measure":"Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24","timeFrame":"Up to 6 weeks (between Weeks 19 and 24)","effectByArm":[{"arm":"Efgartigimod PH20 SC","deltaMin":13.7,"sd":null},{"arm":"Placebo PH20 SC","deltaMin":16.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5081"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":25},"locations":{"siteCount":200,"countries":["United States","Argentina","Australia","Bulgaria","Chile","China","Denmark","France","Georgia","Germany","Greece","Ireland","Israel","Italy","Japan","Jordan","Mexico","New Zealand","Norway","Poland","Portugal","Romania","Russia","Serbia","South Africa","South Korea","Spain","Taiwan","Thailand","Tunisia","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":137},"commonTop":["Blood urine present","Haematuria","Ecchymosis","Petechiae","Epistaxis"]}}